Word cloud with key elements of an Active Learning Classroom. حسب Mairena Sánchez-López (684092)

الموضوعات:

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters حسب Arash GhorbanniaDelavar (22563696)

"…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …"

Point cloud fusion instance effect. حسب Hongliang Zou (20707270)

الموضوعات:

Thematic clouds for lectures. حسب Ignacio García-Espona (21395335)

Displacement cloud maps. حسب Maogang Tian (21485116)

Madrasin decreases transcription of protein-coding genes. حسب Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. حسب Michael Tellier (8284752)

Introgression decreases allelic shuffling. حسب Enrique J. Schwarzkopf (6579275)

Thematic cloud for posters [2013-23]. حسب Ignacio García-Espona (21395335)

Why does task performance decrease with burst length? حسب Swathi Anil (17382903)

CS rates increased with protraction and decreased with retraction. حسب Paul Hage (21071783)

Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 3_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 6_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 2_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx حسب Jianwei Hong (6918776)

"…</p>Results<p>KEGG enrichment analysis indicated that the NF-kappa B and TNF signaling pathways may be associated with COPD and NASH co-morbidities. Ten small-molecule drugs associated with COPD and NASH were identified through cMAP analysis, including ansoprazole and atovaquone. …"

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

"…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"

The Mach number cloud distribution on three cross sections at different HBRs. حسب Jingya Dong (19959282)

Sensitivity to small changes. حسب Ariel Burman (20329776)